Why It Matters
Mifepristone, the drug at the center of a multi-front legal and political battle, is now the subject of a formal federal regulatory petition. The medication is a core component of the two-drug abortion regimen that accounted for close to two-thirds of all clinician-provided abortions in states without abortion restrictions in 2023. An EPA decision to add it to the Contaminant Candidate List would open the door to expanded testing mandates and regulatory review.
What Happened
A coalition of 14 Republican state attorneys general submitted a letter last Friday to EPA Administrator Lee Zeldin, asking the agency to formally designate mifepristone as a water contaminant. The signatory states span a broad geographic range: Alabama, Alaska, Arkansas, Florida, Idaho, Indiana, Kansas, Kentucky, Louisiana, Missouri, Nebraska, Oklahoma, South Carolina, and Texas.
Simultaneously, a separate letter carrying the signatures of 19 Republican members of Congress arrived at the EPA making the same request. Representative Chris Smith of New Jersey organized and led the congressional effort.
Louisiana Attorney General Liz Murrill, one of the petition’s prominent signatories, argued that growing mifepristone use demands federal attention. “As the use of mifepristone continues to increase, the EPA has a responsibility to investigate potential threats to our drinking water, and this drug should be added to the Contaminant Candidate List for further evaluation,” she said.
The attorneys general contend the drug may enter municipal water supplies through human excretion or the disposal of pharmaceutical waste, potentially exposing pregnant women who consume tap water to unintended doses at harmful concentration levels.
What Scientists Say
Environmental health researchers have found no credible evidence linking mifepristone in wastewater to harm for people or ecosystems. The Center for Biological Diversity has stated publicly that there is no documented indication that medication abortion affects U.S. water systems in any meaningful way.
The FDA reached a similar conclusion decades earlier. In a 1996 statement, the agency said it did not anticipate any harmful environmental effects from mifepristone — a position that has not been scientifically overturned in the years since.
By the Numbers
- 14 Republican attorneys general signed the petition to EPA
- 19 GOP members of Congress submitted a concurrent request
- Nearly two-thirds of clinician-provided abortions in states without bans involved medication abortion in 2023
- 9 bills invoking environmental or water-safety arguments related to abortion drugs were introduced across 7 states in 2025
- 1996 — the year the FDA first concluded that harmful environmental effects from mifepristone were not expected
Zoom Out
The EPA petition represents one strand of a larger strategy by Republican-led states to challenge mifepristone’s availability through regulatory and legal avenues that operate independently of direct abortion legislation. State-level interest in the environmental angle is growing: in 2025 alone, lawmakers across seven states introduced nine separate bills citing water-safety or environmental concerns tied to medication abortion. A similar congressional letter was delivered to the EPA the year before.
The legal picture around mifepristone is also actively shifting. Last month, the U.S. Supreme Court moved to preserve telehealth access to the drug while the Fifth Circuit Court of Appeals takes up the underlying dispute in Louisiana v. Food and Drug Administration — a case in which Murrill’s office plays a central role.
What’s Next
The EPA has not signaled whether it intends to act on the petition. Placing a substance on the Contaminant Candidate List is a formal procedural step that would require scientific review and a public comment period before any binding regulatory action could follow. The Fifth Circuit’s eventual decision in the Louisiana case may reshape the broader legal framework governing mifepristone access, with consequences that reach well beyond water-quality policy.